The second Danish study, also led by Dr Orsted, looked at whether prostate-specific antigen
levels could predict prostate cancer incidence and mortality in the general population.
19,24] Prostate-specific antigen
velocity alone should not be the basis for a decision to biopsy.
(PSA)  had been in clinical use for several years when we encountered a problem with 2 samples that did not give expected results upon dilution.
As part of the Tyrol Prostate-Specific Antigen
Screening Project (J.
respond to "condom effectiveness and prostate-specific antigen
," American Journal of Epidemiology, 2003, 157(4):301-302.
1) In 1979, Wang, et al, purified a protein from prostate tissue, (2) confirmed the identity to the earlier protein and established today's familiar term, prostate-specific antigen
The issuance of these patents join Calydon's collection of patents covering viral therapeutics that target and treat prostate and other cancers which includes United States Patent 5,698,443 and United States Patent 5,871,726 that cover methods for constructing a virus that incorporates the prostate-specific antigen
enhancer gene for use in specifically targeting and killing prostate cancer cells; United States Patent 5,830,686 and United States Patent 5,648,478 that claim a human prostate tissue-specific enhancer gene and methods that utilize the prostate-specific antigen
enhancer gene for treating prostate disease; and United States Patent 5,783,435 that claims methods and compositions for screening therapeutic agents for the treatment of prostate cancer.
Tests to determine the amount of prostate-specific antigen
(PSA), a protein produced by the cells of the prostate gland, in the blood along with a digital rectal exam is used to help initially detect prostate cancer and is also used to monitor patients with a history of prostate cancer to see if the cancer has come back, or recurred.
testing for early diagnosis of prostate cancer.
A complex between prostate-specific antigen
and a 1-antichymotrypsin is the major form of prostate-specific antigen
in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.
Measuring serum levels of total prostate-specific antigen
(PSA) hits a gray zone between 2.
For instance, physicians look at high blood concentrations of a protein called prostate-specific antigen
as an indication of prostate cancer.